Beximco Pharmaceuticals Ltd

BXP

Equity

ISIN null / Valor 2318407

LSE London Stock Exchange, SETS (2026-03-31)

GBP 0.42%

Beximco Pharmaceuticals Ltd
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Beximco Pharmaceuticals Ltd., established in 1976 and headquartered in Dhaka, Bangladesh, is a prominent manufacturer and exporter of medicines and active pharmaceutical ingredients (APIs). Initially, the company began by importing and selling products from Bayer AG and Upjohn Inc. in the local market, later transitioning to manufacturing these products under licensing agreements in 1980. By 1983, Beximco Pharma had launched its own formulation brands. Over the years, the company has expanded significantly, now exporting to over 50 countries, including highly regulated markets such as the USA, Europe, Canada, and Australia. Beximco Pharma's manufacturing facilities are accredited by leading global regulatory authorities. The company employs over 4,700 professionals across various disciplines. In recent strategic moves, Beximco Pharma acquired a majority stake in Sanofi Bangladesh Limited in 2021, which was subsequently renamed Synovia Pharma PLC. The company is also notable for being the only Bangladeshi firm listed on the AIM of the London Stock Exchange.

Summarized from source with an LLMView SourceSector: Healthcare

Headline financials (Half year)

Net sales rose 8.8% year‑on‑year to BDT 24,013.4m (£161.5m). Profit after tax increased 17.5% to BDT 3,535.0m (£23.8m). Earnings per share for the six months were Tk 7.87 (vs Tk 6.69 a year earlier). NAV per share improved to Tk 111.35 (Dec 31, 2024) from Tk 101.11 a year earlier.

Quarter (Q2 Oct–Dec 2024) performance

Q2 net sales rose 12.8% to BDT 12,299.6m (£82.7m) and profit after tax rose 27.9% to BDT 1,843.1m (£12.4m). Q2 EPS was Tk 4.10 (vs Tk 3.21 in Q2 prior year).

Revenue mix & export growth

Domestic sales were BDT 22,262.3m (+7.4% YoY) while export sales grew 31.6% to BDT 1,751.1m, reflecting stronger international registrations and new export markets.

Profitability & margins

Gross profit for the half was BDT 10,978.6m (gross margin ≈45.7%), up from ~44.4% a year earlier. Operating profit was BDT 5,087.6m (operating margin ≈21.2%). Net margin improved to ~14.7% for the half.

Cash flow, capex and balance sheet

Net cash from operations was BDT 2,734.8m (down from BDT 4,467.7m prior year). Cash and cash equivalents increased to BDT 1,655.3m at 31 Dec 2024. Capex (PP&E) during the half was BDT 1,526.6m. Total equity was BDT 53,628.96m and total assets BDT 73,802.18m.

Leverage & liabilities

Short‑term borrowings stood at BDT 3,060.4m with long‑term borrowings (net of current maturity) BDT 2,024.5m. Total liabilities were BDT 20,173.22m, supporting a strong equity base.

Operational & international progress

The company launched four new products in Bangladesh, secured 28 new registrations for 27 products across five countries, and commenced exports to four new countries (Cuba, Malta, Qatar and Angola).

Management & outlook

Management highlighted “strong, profitable growth” despite macro challenges and expects to build on international registration and export momentum in the second half of the year.

Summarized from source with an LLMView Source

Key figures

10.1%1Y

9.25%3Y

-51.4%5Y

Performance

29.4%1Y

49.7%3Y

53.3%5Y

Volatility